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Abstract 
Objective 
To evaluate the evolution of our surgical experience with the implantation of a continuous flow left 
ventricular assist device (LVAD), from the original full sternotomy approach to less invasive surgical 
strategies including mini-sternotomy and/or mini-thoracotomies. 
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Methods 
We reviewed all consecutive patients implanted with a continuous flow LVAD at our Institute. To 
exclude the possible bias related to the device used, out of 91 collected LVADs implants, we selected 
only those patients (n=42) who received, between 2012 and 2015, the HeartWare HVAD. The 
analysis focused on the surgical approach used for the LVAD implant. Most of the patients (95%) 
were affected by dilated or ischemic cardiomyopathy, with an INTERMACS class I-II in the majority 
of cases (86%). 
 
Results 
The LVAD implant was performed through a full sternotomy in 10 patients (24%); the remaining 32 
cases (76%) were managed with minimally invasive procedures. These were left mini-thoracotomy 
with upper mini-sternotomy (20 patients, 62%), right and left mini-thoracotomy (7 patients, 22%) and 
a recently developed left mini-thoracotomy with outflow graft anastomosis to the left axillary artery 
(5 patients, 16%). The most common adverse event on device was right heart failure (26%). Eighteen 
patients (43%) were transplanted. Overall estimated 24 months survival (on device or after transplant) 
was 68±7%. The causal analysis, adjusted by propensity score weighting baseline data and sample 
size, showed that left mini-thoracotomy with outflow anastomosis to the left axillary artery resulted in 
a significantly reduced rate of post implant right heart failure (p<0.01), and mechanical ventilation 
time (p=0.049). 
 
Conclusions 
In our series, by applying mini-invasive implant techniques in the majority of cases, mid-term 
survival of continuous flow LVADs in severely compromised patients was satisfactory. In the 
adjusted analysis, the left anterior mini-thoracotomy with outflow anastomosis to the left axillary 
artery showed the most favourable results. 
 
Keywords: Left Ventricular Assist Device; HeartWare; HVAD; minimally invasive; implant; surgical 
technique 
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Main text 
Introduction 
During the last decades, left ventricular assist devices (LVADs) have become a viable therapeutic 
option for patients with end-stage heart failure1–4. First generation LVADs were bulky and space-
demanding devices; thus, in the early era, the standard surgical approach for LVADs implantation was 
limited to the full median sternotomy5. Subsequent improvements in pump technology and design, 
with a progressive miniaturization of the devices, enhanced their performance and reliability and 
allowed the development of less invasive implantation strategies. Several minimally invasive 
techniques have been, so far, proposed, such as left mini-thoracotomy combined with an upper mini-
sternotomy, or combination of right and left mini-thoracotomies6–8. Since this is a novel and evolving 
field, the results of minimally invasive procedure for LVAD implant are still under investigation. 
Here we describe these techniques and focus on the latest developed surgical approach, consisting in a 
left mini-thoracotomy for exposure of the left ventricular apex combined with the left axillary artery 
surgical isolation, where the outflow graft anastomosis is performed. The aim was to analyse and 
compare the results of the standard sternotomy approach and of the different minimally invasive 
implant techniques. 
 
Materials and Methods 
Study design and patient population 
This is a single-centre retrospective study on prospectively collected data. We reviewed all 
consecutive patients who received a continuous flow LVAD at our Institution from 2008 to 2015. 
During this period, we implanted 91 patients: 49 (54%) received the Jarvik 2000 (Jarvik Heart, Inc., 
Manhattan, NY, USA), and 42 (46%) the HeartWare HVAD (HeartWare Inc., Framingham, MA). To 
exclude a possible bias related to the device used, we selected for the analysis only the HeartWare 
HVAD patients. These were implanted between 2012 and 2015, when our expertise in the 
management of mechanical circulatory supports was already established. The study was approved by 
the Institutional Review Board; an individual patient consent was waived.  
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Adverse events on device were classified according to the INTERMACS definitions1. 
 
Surgical technique 
Here we systematically describe the possible surgical approaches for LVADs implantation, focusing 
on tricks and traps of minimally invasive techniques. These consist in the left anterior mini-
thoracotomy (LMT) for left ventricle apex exposure, combined with one of three possibilities: 1) the 
upper mini-sternotomy (UMS); 2) the right anterior mini-thoracotomy (RMT); 3) the left axillary 
artery isolation (LAA). The first two options entail performing the outflow graft anastomosis at the 
ascending aorta, whereas in the last case the outflow is connected to the left axillary artery (Figure 1). 
In our experience, the first 10 cases (24%) of HVAD implantation were performed through a full 
median sternotomy. Thereafter, the path evolved towards less invasive approaches and the LMT was 
combined with UMS in 20 patients (48%), with RMT in 7 patients (17%), and with LAA in 5 patients 
(12%). 
 
When a minimally invasive approach is employed, the first surgical step is the execution of the LMT 
with left ventricle apex exposure and positioning of the sewing ring. Subsequently, the UMS or the 
RMT is performed, the LVAD inflow is inserted into the left ventricle and the outflow graft is 
tunnelled through the pericardium and anastomosed to the ascending aorta. Those cases managed with 
left axillary artery isolation enable a different surgical plan, which will be described later in the 
dedicated part. 
 
Left anterior mini-thoracotomy 
The patient is placed in supine position and a pillow or a gel pad is used to elevate the chest at the 
interscapular level, as for a sternotomy access. The skin incision is performed just below the areola in 
men, and at the inframammary groove in women. The intercostal space to access is chosen depending 
on the position of the apex (usually it corresponds to the fifth intercostal space), which can be 
identified by palpation or with the aid of echocardiography. Once the pericardium is exposed and 
opened, the left ventricular apex is available without any further heart manipulation. The correct 
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insertion site of the LVAD is localized on the left ventricular wall by echocardiographic assessment, 
using a finger pushed on the apex to simulate the inflow cannula. A dermographic pen can be used to 
mark this site. The sewing ring is, then, secured with interrupted pledgetted 2-0 polypropylene 
sutures. 
 
Upper mini-sternotomy 
An inverted T-shape mini-sternotomy is performed by sawing the sternal manubrium only or together 
with a part of the sternal body, up to the third-forth intercostal space. According to the extension of 
the mini-sternotomy, a different section of the ascending aorta is exposed. When the sternum is 
divided up to the fourth intercostal space, the anastomosis of the outflow graft will correspond to the 
anterior face of the aorta, near the sino-tubular junction. In the case the sternum is split up to the third 
intercostal space, the anastomosis will be performed at the front face of the ascending aorta in an 
intermediate position. In cases of isolated sternal manubrium division, the anastomosis will be 
performed in the front position of the aorta, but very close to the emergence of the brachiocephalic 
artery. The outflow vascular graft is tunnelled underneath the pericardium from the LMT to the UMS 
and is accurately arranged and measured in order to cut at the right length, without kinking or 
overstretching it. 
 
Right anterior mini-thoracotomy 
The LVAD implantation through a RMT starts with an incision at the second right intercostal space. 
The incision, of almost 4-5 cm, is performed proximally to the body of the sternum with a lateral 
direction, along the correspondent intercostal space. Once opened the pericardium longitudinally, and 
suspended to the skin in its proximal (next to the first operator) edge, in the foreground appears the 
ascending aorta, on a lower level lies the superior vena cava, while the right atrial appendage extends 
to the most proximal part of the aorta. The pulmonary artery, instead, runs much deeper and medial in 
the surgical field. When the implantation of a right ventricular assist device (RVAD) is required, the 
only way to expose it is to release the proximal pericardial suspension and to pull on the distal 
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pericardial edge until a slight twisting of great vessels axis is achieved, to get the pulmonary artery in 
a higher plane respect to the aorta.  
 
After great vessels exposure, the outflow graft is tunnelled through the LMT underneath the 
pericardium, using a blunt-tip instrument, and is stretched to the RMT. The vascular graft is 
anastomosed, then, to the lateral face of the ascending aorta, in its intermediate portion. 
 
Left axillary artery outflow graft anastomosis 
So far, this implant technique exclusively applies to the HVAD, due to its peculiar outflow graft size 
(10 mm of diameter). Other currently available devices provide a larger vascular prosthesis, which are 
incompatible with the usual size of the axillary artery. 
 
This approach enables a different surgical plan: after LMT, the axillary artery isolation and the 
outflow graft anastomosis can be performed first, followed by the connection to the LVAD and its 
insertion into the left ventricular apex in a second step.  
 
There are two possible surgical incision: sub-clavicular incision and delto-pectoral incision.  
 
The sub-clavicular incision is performed through a 6-8 cm incision below and parallel to the lateral 
two-thirds of the clavicle. The axillary artery, in its proximal portion, is located just below the vein, 
and, once circled, it can easily be mobilized and externalized. 
 
A further approach to the axillary artery is the so-called delto-pectoral incision, which allows access 
to the second (median) portion of the vessel. This more peripheral surgical approach is preferred in 
the presence of a defibrillator in the sub-clavicular position. The skin incision of nearly 5 cm is 
performed in the delto-pectoral groove, along the line that connects the midclavicular line with the 
point of intersection between the anterior margin of the deltoid and the side edge of the biceps muscle. 
In this position, the median nerve crosses the artery, while the vein remains anteromedial. The axillary 
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artery is exposed by inferiorly mobilizing the nerve. Particular attention must be paid, to respect the 
nerve structures during both artery dissection and vascular clamp placement. 
 
Generally, the calibre of the axillary artery is less than 8 mm, while the diameter of HVAD vascular 
prosthesis is 10 mm. According to the dimension of the artery, we apply different surgical procedures 
to perform the outflow graft anastomosis (Figure 2), as follows: 
 
A. Axillary artery diameter >8 mm 
After placing the vascular clamp proximally and distally, the artery is cut crosswise. The 
proximal portion of the axillary artery is end-to-end anastomosed to the HVAD vascular 
prosthesis with a 5-0 polypropylene suture. Thereafter, the distal portion of the axillary artery is 
end-to-side anastomosed to the vascular prosthesis (Figure 2 – A). 
B. Axillary artery diameter <8 mm 
This is the more common case, which we manage by interposing a 2-2.5 cm length of vascular 
prosthesis of 8 mm in diameter to the axillary artery, to create a prosthetic bridge along its 
course. After clamping, the axillary artery is transversely interrupted, and the vascular prosthesis 
is end-to-end anastomosed proximally and distally, using 5-0 polypropylene sutures. An incision 
is, then, performed on the interposition graft, along the long axis of the vessel and the LVAD 
outflow graft is end-to-side connected with it (Figure 2 – B). 
The distal portion of the axillary artery is banded, to avoid a preferential flow to the left arm. Once the 
LVAD outflow is anastomosed, it has to be tunnelled within the chest. In both types of incision, we 
choose the first intercostal space as entry point. Through the same access used for the graft 
anastomosis, with the aid of a retractor, the muscle pectoralis major is gently mobilized to expose the 
first intercostal space. An umbilical tape is introduced from the LMT through this space. At this point, 
an armed Gore-Tex vascular prosthesis is tunnelled through the thorax following the tape. The Gore-
Tex prosthesis stands for protection of the outflow graft along the intrathoracic course, and in the 
way-out of the chest through the intercostal space. The outflow graft is tunnelled inside the Gore-Tex 
prosthesis and, then, connected to the LVAD. 
A
cc
ep
te
d 
A
rt
ic
le
This article is protected by copyright. All rights reserved. 
Statistical analysis 
Continuous data are presented as median and interquartile range (IQR); discrete variables are 
expressed as number and percentages. Categorical variables were compared with the chi-square test or 
the Fisher’s exact test, when appropriate. Continuous variables were compared with the t test or by 
one-way analysis of variance (to compare multiple groups). Survival curves were drawn by competing 
risk analysis. Statistical significance was set at a p-value <0.05.  
 
A causal analysis was conducted to estimate the effect of surgical access on several outcomes. 
Propensity score analysis was targeted to the average treatment effect on the population (ATE), which 
answers the question of how, on average, the outcome of interest would change if everyone in the 
population had been assigned to a particular treatment rather than all receiving another single 
treatment. Propensity weights have been estimated by Generalized Boosted Models (GBM)9 using 
sex, age at implant, INTERMACS profile, primary cardiac diagnosis, glomerular filtration rate 
(GFR), serum bilirubin, tricuspid annular plane systolic excursion (TAPSE) at echocardiogram, pre-
operative ECMO implantation and follow-up time as covariates. GBM has been implemented as a 
tree-based regression model built in an iterative fashion (10000 iterations each). Kolmogorov-
Smirnov (KS) statistics was used as stopping rule and balance measure and its maximum for 
summarizing across balance metrics. Causal effect of surgical access on outcomes was estimated by 
propensity score-adjusted Generalized Linear Models. Quasi-binomial models have been used for 
right heart failure (severe-acute and severe), major bleeding, 30-days mortality and presence of 
cerebral fatal and non-fatal events (ischemic and haemorrhagic). For talking skewness in the data 
distribution, GLM for mechanical ventilation time, ICU stay and in-hospital stay was built using a 
Gamma with log-link function. 
 
The statistical analysis was performed using the “R” system10. 
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Results 
Between 2012 and 2015, 42 patients underwent HVAD implantation at our Institution. Median age at 
implant was 52 years (IQR: 40-58). Baseline patient’s characteristics are summarized in Table 1. 
Most of the cases were in INTERMACS profiles I-II (86%). Overall, 8 (19%) patients required 
preoperative support with intra-aortic balloon pump (IABP), 16 (38%) were on extracorporeal 
membrane oxygenation (ECMO) and 4 (10%) on para-corporeal LVAD. Patients implanted through 
different surgical approaches had comparable baseline characteristics (Table 1). Fourteen patients 
(44%) received off-pump and 12 (38%) on-ECMO implantation of LVAD in the mini-invasive group. 
On the contrary, all full sternotomy cases were managed with the aid of cardiopulmonary bypass, 
except for one case of on-ECMO implantation. 
 
Post implant outcomes overall and by surgical approach adopted are detailed in Table 2. Right heart 
failure (severe-acute and/or severe) occurred in 11 cases (26%) and was the most common adverse 
event on device, considering both at implant and surveillance periods. Among these, 8 (19%) patients 
experienced sever-acute RHF, requiring RVAD implant.  Thirty-day mortality was 17 % (n=7); other 
six deaths occurred during a median follow-up of 22 months (IQR 7-32), thus, the overall observed 
mortality was 31% (n=13). Eighteen patients (43%) underwent heart transplant. Estimations of overall 
survival at 12 and 24 months were 71±7% (95% Confidence Interval – 95% CI: 68-74) and 68±7% 
(95% CI: 64-72); whereas the probabilities to undergo heart transplant were 37±10% (95% CI: 31-43) 
and 45±10% (95% CI: 29-61), respectively (Figure 3). Unadjusted univariate analysis of outcomes 
showed comparable results among patients managed with standard (full sternotomy) or minimally 
invasive surgical approach (Table 2).  
 
To evaluate the impact of each technique on results, we performed a causal analysis adjusted by 
propensity score weighting baseline data, follow up time and sample size. Effective Sample Sizes 
(ESS) were 9.56 for full sternotomy, 18.67 for LMT-UMS, 6.99 for LMT-RMT and 4.99 for LMT-
LAA. Effects of surgical access on outcomes, both crude and after propensity score adjustment, are 
presented in Table 4. Left anterior mini-thoracotomy combined to left axillary artery isolation showed 
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a significantly reduced rate of post implant right heart failure (severe-acute and/or severe) (p<0.01), 
and mechanical ventilation time (p=0.049), in the adjusted analysis. 
 
Discussion 
In the current era, where the number of available donor hearts is insufficient to meet the needs of 
patients waiting for heart transplant, the LVAD therapy has increasingly gained relevance 
worldwide1–3,11. Minimally invasive procedures in cardiac surgery are known to be associated with 
many favourable effects, such as reduction of blood loss and rate of infections, leading to improved 
outcomes12. With the reduced profile and dimension of the newest generation devices, the use of 
minimally invasive techniques is, nowadays, possible even for LVADs implantation6,13–16. Thus, the 
emerging question is whether these surgical approaches should be always pursued or not17. 
 
Although the full median sternotomy provides the best and easiest access to the heart and the adjacent 
structures, it has many detrimental effects. Median sternotomy decreases lung volumes and reduces 
thoracic motion with significantly lowered functional residual capacity and total lung capacity months 
later. This, combined with a higher postoperative pain, can lead to respiratory failure or a prolonged 
mechanical ventilation time18. Moreover, the increased surgical trauma exposes the patient to a greater 
risk of bleeding and infection12. The typical LVAD candidate is physically compromised, fragile, 
often with impaired pulmonary and renal function
19–22
 and may not have sufficient resources to 
tolerate major surgical insults. Therefore, device implant through smaller, less traumatic incisions is a 
desirable goal, which could help achieving a faster postoperative recovery. Bedridden patients 
inevitably develop muscle atrophy, which compromises respiratory mechanics and prolong wound 
healing, while an early implementation of exercise training represent a key therapeutic intervention in 
frail patients23. Nonetheless, the favourable effects of minimally invasive LVAD implantation can go 
far beyond a fastened physical recover: some authors showed a decrease in the rate of right heart 
failure compared to the standard surgical approach24,25. This has been linked to the avoidance of 
pericardial opening, which could allow for a preservation of right ventricle geometry and, therefore, 
function26. Another important advantage of mini-invasive techniques is the possibility to implant the 
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device without using the cardiopulmonary bypass27. In fact, the thoracotomy approach to the left 
ventricle apex allows for the LVAD insertion without heart manipulations, which could cause 
haemodynamic decline. The avoidance of cardiopulmonary bypass enables a reduction in the heparin 
dose administered, decreasing the risk of bleeding, and in the inflammatory response, improving the 
postoperative course
24
. On the other hand, the minimally invasive techniques for LVADs implantation 
are complex procedure and, thus, can be applied only in experienced centre, by well-trained teams. 
 
In this study, we reviewed our surgical experience with HeartWare HVAD and described the 
available techniques for mini-invasive implantation. We first evolved from the full sternotomy to the 
left anterior mini-thoracotomy combined with the upper mini-sternotomy. This approach allows for an 
optimal great vessels exposure and enables the possibility of off-pump or on-ECMO implantation. 
Nevertheless, it imposes a partial sternotomy and do not permit the complete preservation of thoracic 
physiology and mechanics. For this reason, we moved to the double (right and left) mini-thoracotomy, 
which has all the advantages of a real sternal-sparing technique. However, in this procedure, the 
outflow anastomosis to the ascending aorta is more demanding due to the narrowed surgical field; 
moreover, the graft tunnelling underneath the pericardium can be particularly complicated in presence 
of a full loaded heart, often preventing the off-pump implantation. Finally, this technique is not able 
to avoid the re-entry risk of a subsequent heart transplant, due to the outflow graft that crosses the 
mediastinum. In the last development, we combined the left anterior mini-thoracotomy with the 
outflow anastomosis to the left axillary artery. This procedure deserves specific considerations. It 
allows an almost complete preservation of mediastinal structures; this unique feature makes it 
preferable in re-do patients or in case of calcified ascending aorta, besides the obvious advantage at 
the heart transplant time. The connection to the left axillary artery presents some technical issues: the 
calibre of the vessel, usually, does not match with that of the graft; the outflow need to be tunnelled in 
the thorax and trough an intercostal space, being subject to kinking or compression; the left arm is at 
risk of overflow. To overcome the first issue, we propose a surgical approach that is dependent on the 
calibre of the LAA. Rare cases with a vessel diameter >8 mm are managed with end-to-end graft 
anastomosis and end-to-side connection of distal LAA (Figure 2 – A). Whereas, when the calibre is 
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<8 mm (which is the usual condition), we first interpose a prosthetic bridge along the LAA course, 
then, we perform an end-to-side graft anastomosis (Figure 2 – B). Other authors reported a direct end-
to-side anastomosis28; we prefer using the prosthetic bridge to expand the lumen of the LAA (up to 8 
mm) and avoid a potential narrowing at the anastomosis site. To simplify the procedure and reduce 
the operative time, the outflow anastomosis can be performed as a free graft, with subsequent 
tunnelling in the thorax and connection to the LVAD in a second step, though the strain-relief 
placement through the LMT could result troublesome. The use of a double-lumen endotracheal tube 
for mechanical ventilation can facilitate this part, allowing for a temporary exclusion of the left lung. 
To avoid kinking or compression of the outflow graft in its course within the chest and the intercostal 
space, we cover it with an armed Gore-Tex prosthesis. Finally, to prevent preferential left arm flow, 
which could cause reduced systemic perfusion and arm swelling, we perform a bending of the LAA 
distal to the graft anastomosis, guided by a continuous pressure monitoring of both radial arteries. The 
distal flow in the left arm is assessed after pump start and the bend is tightened until the pressure in 
both arms is equalized. Another advantage of LAA use is the possibility to fine-tune the deairing 
phase. After performing the anastomosis of the graft and its connection with the LVAD, a first device 
deairing is performed retrogradely. Subsequently, the LVAD is inserted in the left ventricle and the 
system is deaired, by low-speed pump activation, through a fine needle placed distally in the outflow 
graft. This main, antegrade, deairing is performed keeping a clamp on the LAA proximal to the 
anastomosis, in order to prevent potential air embolism to the cerebral vessels. Despite the numerous 
presented pros, the LAA use has also significant cons. First, cases of severe-acute right heart failure, 
requiring RVAD placement, have not a straightforward management. In these cases, to expose the 
pulmonary artery, which is not directly accessible, an additional surgical access is required. We 
encountered this situation in one patient, which we managed by direct cannulation of the pulmonary 
artery through a small left mini-thoracotomy in the second intercostal space. This approach is 
relatively simple and guarantees a good exposure of the target vessel, avoiding more invasive 
procedures; emergent situations can be initially stabilized by peripheral ECMO. Moreover, there are 
concerns regarding possible LVAD flow alterations due to the anastomosis with the LAA, that could 
be subject to narrowing when the left arm is extensively elevated or could be at increased risk of graft 
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thrombosis28. No data, so far, support these hypotheses. In our series, we observed an initial 
restriction of pump flow (to 2.5-3 L/min) that progressively increased to normal values within the first 
week; no significant arm swelling or neurapraxia was noticed. There were no significant mean arterial 
pressure differences among the arms after implant or during follow-up. We educated the patients not 
to overextend (above the head) the left arm and unexpected flow losses were not experienced. This 
was a minor movement restriction, which did not significantly affect patient’s activities. On the other 
hand, INTERMACS-defined suspected pump thrombus was detected in one out of five patients and 
could solve after increasing the anticoagulant and antiplatelet therapy, suggesting that a higher 
antithrombotic level is advisable in these patients.  
 
Our experience bases on severely compromised patients with an INTERMACS profile I-II in 86% of 
cases (85% in the minimally invasive group). This makes our series unique and precludes a possible 
comparison with the present reports in the literature7,13,24,25,28. The number of severe adverse events 
observed was relatively high. However, it should be considered again the critical status characterizing 
most of the patients at baseline. Moreover, we reported a cumulative rate of complications that 
included both at implant and surveillance periods. Anyhow, by applying mini-invasive techniques in 
the majority of cases (76%) the overall mid-term survival was satisfactory. RHF was the most 
frequent adverse event and 19% of cases required temporary RVAD implant. Pre-implant right 
ventricular (RV) function was comparable among patients undergoing different surgical approaches. 
As a matter of fact, in this study, the implant technique was applied independently of RV function. 
We investigated the effect on outcomes of the different techniques used by means of propensity 
weighted causal analysis. In this adjusted comparison, the LMT with outflow anastomosis to LAA 
resulted in a significant reduction of the rate of right heart failure (INTERMACS-defined, severe-
acute and severe) and of mechanical ventilation time. Thus, in our series, the last developed technique 
was the most effective in improving post implant outcomes. Of course, this result should be taken 
cautiously, as the small number of cases managed with each procedure limited our analysis, despite 
the advanced statistical method applied. We believe that, expanding the number of treated patients, 
A
cc
ep
te
d 
A
rt
ic
le
This article is protected by copyright. All rights reserved. 
the favourable effect of mini-invasive approaches will definitely be highlighted, as seen in other fields 
of cardiac surgery.      
 
Conclusions 
In our series, by applying mini-invasive implant techniques in the majority of cases, mid-term 
survival of continuous flow LVADs in severely compromised patients was satisfactory. In the 
adjusted analysis, the left anterior mini-thoracotomy with outflow anastomosis to the left axillary 
artery showed the most favourable results. We believe that, expanding the experience, mini-invasive 
procedures will establish as the standard approaches for LVAD implant.   
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Table 1 - Baseline patient’s characteristics 
 
All patients 
(n=42) 
FS 
(n=10) 
LMT  UMS 
(n=20) 
LMT RMT 
(n=7) 
LMT   LAA 
(n=5) 
p value 
Female sex 9 (21) 4 (40) 3 (15) 2 (29) 0 (0) 0.25 
Age (years) 52 (40-58) 40 (14-56) 54 (47-60) 47 (44-58) 58 (55-58) 0.06 
INTERMACS Profile      0.08 
I 17 (41) 5 (50) 7 (35) 4 (57) 1 (20)  
II 15 (36) 4 (40) 9 (45) 2 (29) 0 (0)  
III 9 (21) 1 (10) 4 (20) 1 (14) 3 (60)  
IV 1 (2) 0 0 (0) 0 (0) 1 (20)  
Cardiac diagnosis      0.85 
DCM 18 (43) 4 (40) 7 (35) 4 (57) 3 (60)  
ICM 22 (52) 5 (50) 12 (60) 3 (43) 2 (40)  
Other 2 (5) 1 (10) 1 (5) 0 (0) 0 (0)  
Previous cardiac surgery 2 0 1 (5) 0 (0) 1 (20) 0.33 
Preoperative IABP 8 (19) 3 (30) 3 (15) 1 (14) 1 (20) 0.78 
Preoperative ECMO 16 (38) 5 (50) 7 (35) 3 (43) 1 (20) 0.70 
Preoperative para-LVAD 4 (10) 0 1 (5) 2 (29) 1 (20) 0.16 
GFR (ml/min/m2) 88 (55-90) 80 (59-90) 68 (51-89) 89 (65-90) 69 (59-75) 0.73 
Serum bilirubin (mg/dl) 1.1 (0.8-1.9) 1.3 (0.8-1.9) 1 (0.8-1.6) 1.5 (0.7-2.3) 1.2 (0.9-1.5) 0.88 
Echocardiografic data       
LVEF (%) 19 (15-22) 16 (15-23) 20 (16-21) 18 (16-23) 20 (18-24) 0.96 
PASP (mmHg) 43 (39-54) 44 (38-52) 43 (38-46) 40 (33-60) 42 (41-70) 0.44 
TAPSE (mm) 14 (12-16) 12 (8-12) 14 (13-17) 14 (12-15) 15 (15-16) 0.12 
TR      0.14 
Trivial/mild 33 (79) 6 (60) 18 (90) 6 (86) 3 (60)  
Moderate/severe 7 (17) 2 (20) 2 (10) 1 (14) 2 (40)  
Device strategy      0.60 
DT 6 (14) 2 (20) 3 (15) 1 (14) 0 (0)  
BTT 31 (74) 6 (60) 14 (70) 6 (86) 5 (100)  
BTC 5 (12) 2 (20) 3 (15) 0 (0) 0 (0)  
Data are expressed as N (%) or median (IQR) 
Abbreviations used: DCM – dilated cardiomyopathy; ICM – ischemic cardiomyopathy; cardiac diagnosis “other” – hypertrophic 
cardiomyopathy and Carvajal sindrome, IABP – intra aortic balloon pump; ECMO - extracorporeal membrane oxygenation; para-LVAD 
– paracorporeal left ventricular assist device; GFR – glomerular filtration rate; LVEF – left ventricle ejection fraction; PAS - pulmonary 
artery systolic pressure; TAPSE - tricuspid annular plane systolic excursion; TR - tricuspid regurgitation; DT – destination therapy; BTT 
– bridge to transplant; BTC – bridge to candidacy 
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Table 2 – Post implant outcomes by surgical approach adopted 
 
All patients 
(n=42) 
FS 
(n=10) 
LMT UMS 
(n=20) 
LMT RMT 
(n=7) 
LMT LAA 
(n=5) 
Adverse events on device*      
RHF (severe-acute and/or severe)  11 (26) 2 (20) 5 (25) 3 (43) 1 (20) 
RHF severe-acute 8 (19) 1 (10) 4 (20) 2 (29) 1 (20) 
RHF severe 5 (7) 1 (10) 2 (10) 2 (29) 0 (0) 
Major bleeding 9 (21) 3 (30) 3 (15) 2 (29) 1 (20) 
Major infection 10 (24) 3 (30) 4 (20) 2 (29) 1 (20) 
LVAD infection 1 (2) 1 (10) 0 (0) 0 (0) 0 (0) 
Driveline infection 7 (17) 2 (20) 4 (20) 1 (14) 0 (0) 
Sepsis 2 (5) 0 (0) 0 (0) 1 (14) 1 (20) 
Pump thrombus 4 (10) 0 (0) 2 (10) 1 (14) 1 (20) 
Respiratory failure 2 (5) 1 (10) 1 (5) 0 (0) 0 (0) 
Acute renal dysfunction 8 (19) 1 (10) 4 (20) 2 (29) 1 (20) 
Cerebral event 10 (24) 3 (30) 4 (20) 2 (29) 1 (20) 
Ischemic 3 (7) 1 (10) 1 (5) 1 (14) 0 (0) 
Haemorrhagic 4 (10) 2 (20) 1 (5) 1 (14) 0 (0) 
Ischemic-haemorrhagic 3 (7) 0 (0) 2 (10) 0 (0) 1 (20) 
30-day death 7 (17) 1 (10) 3 (15) 1 (14) 2 (40) 
Ischemic stroke 1 (2) 0 (0) 1 (5) 0 (0) 0 (0) 
Haemorrhagic stroke 3 (7) 0 (0) 1 (5) 1 (14) 1 (20) 
MSOF 2 (5) 1 (10) 1 (5) 0 (0) 0 (0) 
Bowel ischemia 1 (2) 0 (0) 0 (0) 0 (0) 1 (20) 
Late death** 6 (17) 3 (33) 3 (18) 0 (0) 0 (0) 
Haemorrhagic stroke 3 (7) 3 (33) 0 (0) 0 (0) 0 (0) 
Bowel ischemia 1 (3) 0 (0) 1 (6) 0 (0) 0 (0) 
G-I bleeding 1 (3) 0 (0) 1 (6) 0 (0) 0 (0) 
Death after HTx 1 (3) 0 (0) 1 (6) 0 (0) 0 (0) 
Overall death 13 (31) 4 (40) 6 (30) 2 (29) 2 (40) 
Heart transplant 18 (43) 5 (50) 11 (55) 2 (29) 0 (0) 
Follow up time (months) 22 (7-32) 27 (7-43) 28 (10-34) 13 (11-19) 8 (1-9) 
Length of support (months) 8 (2-12) 2 (1-6) 9 (4-16) 11 (10-12) 8 (1-9) 
Operative time (min) 240 (190-300) 350 (300-350) 210 (180-253) 220 (190-245) 200 (200-240) 
RBC units transfused at implant 0 (0-1) 1 (1-2) 1 (0-2) 1 (0-1) 0 (0-1) 
* Adverse events on device are considered at LVAD implant and/or at surveillance period 
**Late deaths are considered among 30-day survivors 
Data are expressed as N (%) or median (IQR) 
Abbreviations used: FS – full sternotomy; LMT – left anterior mini-thoracotomy; RMT – right anterior mini-thoracotomy; UMS – upper 
mini-sternotomy; LAA – left axillary artery isolation; RHF – right heart failure; MSOF – multi-system organ failure; G-I – gastro-intestinal; 
HTx – heart transplant 
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Table 3 – Univariate analysis of post implant outcomes 
 
All patients 
(n=42) 
Full 
sternotomy 
(n=10) 
Minimally 
invasive 
(n=32) 
p 
value 
Adverse events on device*     
RHF (severe-acute and/or severe)  11 (26) 2 (20) 9 (28) 1.00 
RHF severe-acute 8 (19) 1 (10) 7 (22) 0.66 
RHF severe 5 (7) 1 (10) 4 (13) 1.00 
Major bleeding 9 (21) 3 (30) 6 (19) 0.66 
Major infection 10 (24) 3 (30) 8 (25) 1.00 
LVAD infection 1 (2) 1 (10) 0 (0) 0.24 
Driveline infection 7 (17) 2 (20) 5 (16) 1.00 
Sepsis 2 (5) 0 (0) 2 (6) 1.00 
Pump thrombus 4 (10) 0 (0) 4 (13) 0.56 
Respiratory failure 2 (5) 1 (10) 1 (3) 0.42 
Acute renal dysfunction 8 (19) 1 (10) 7 (22) 0.66 
Cerebral event 10 (24) 3 (30) 7 (22) 0.69 
Ischemic 3 (7) 1 (10) 2 (6) 1.00 
Haemorrhagic 4 (10) 2 (20) 2 (6) 0.24 
Ischemic-haemorrhagic 3 (7) 0 (0) 3 (9) 1.00 
30-day death 7 (17) 1 (10) 6 (19) 1.00 
Ischemic stroke 1 (2) 0 (0) 1 (3) 1.00 
Haemorrhagic stroke 3 (7) 0 (0) 3 (9) 1.00 
MSOF 2 (5) 1 (10) 1 (3) 0.42 
Bowel ischemia 1 (2) 0 (0) 1 (3) 1.00 
Late death** 6 (17) 3 (33) 3 (12) 0.64 
Haemorrhagic stroke 3 (7) 3 (33) 0 (0) 0.01 
Bowel ischemia 1 (3) 0 (0) 1 (4) 1.00 
G-I bleeding 1 (3) 0 (0) 1 (4) 1.00 
Death after HTx 1 (3) 0 (0) 1 (4) 1.00 
Overall death 13 (31) 4 (40) 9 (28) 0.70 
Heart transplant 18 (43) 5 (50) 13 (41) 0.72 
Follow up time (months) 22 (7-32) 27 (7-43) 19 (7-31) 0.32 
Length of support (months) 8 (2-12) 2 (1-6) 10 (4-13) 0.21 
Operative time (min) 240 (190-300) 350 (300-350) 210 (180-250) <0.01 
RBC units transfused at implant 0 (0-1) 1 (1-2) 1 (0-1) 0.41 
* Adverse events on device are considered at LVAD implant and/or at surveillance period 
**Late deaths are considered among 30-day survivors 
Data are expressed as N (%) or median (IQR) 
Abbreviations used: RHF – right heart failure; MSOF – multi-system organ failure; G-I – gastro-intestinal; HTx – heart transplant 
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Table 4. Causal analysis of the effect of surgical approach adopted on outcomes 
Each technique is tested respect to LMT-RMT. Values are coefficients on the linear predictor scale (Coeff), standard errors (SE), 
Confidential Interval at 95% (95% CI) and p-values. 
Variables Unadjusted analysis  Propensity score weighted analysis 
 Coeff SE 
Lower 
95% CI 
Upper 
95% CI 
p 
value 
 Coeff SE 
Lower 
95% CI 
Upper 
95% CI 
p 
value 
Right heart failure* 
FS 0.07 1.07 -2.0 2.2 0.95  0.13 1.11 -2.0 2.3 0.90 
LMT-UMS - 0.47 0.99 -2.4 1.5 0.64  0.01 1.02 -2.0 2.0 0.99 
LMT-LAA - 16.70 1745.8 -3438.5 3405.1 0.99  - 18.10 0.98 -20 -16.2 <0.01 
Major bleeding 
FS 1.32 1.11 -0.9 3.5 0.24  1.15 1.08 -1.0 3.3 0.29 
LMT-UMS - 0.82 1.10 -3.0 1.3 0.46  - 0.79 1.07 -2.9 1.3 0.46 
LMT-LAA 0.51 1.30 -2.0 3.1 0.70  0.50 1.25 -2.0 3.0 0.69 
Mechanical ventilation time 
FS - 0.001 0.001 -0.01 0.01 0.48  - 0.001 0.001 -0.01 0.01 0.28 
LMT-UMS - 0.001 0.001 -0.01 0.01 0.34  - 0.001 0.001 -0.01 0.01 0.11 
LMT-LAA - 0.001 0.001 -0.01 0.01 0.18  - 0.001 0.001 -0.01 -0.01 0.049 
Non-fatal cerebral events** 
FS - 1.28 1.42 -4.1 1.5 0.37  - 1.50 1.36 -4.2 1.2 0.28 
LMT-UMS 0.30 1.01 -1.7 2.3 0.77  0.30 0.99 -1.6 2.2 0.76 
LMT-LAA - 0.47 1.47 -3.4 2.4 0.75  - 0.48 1.41 -3.2 2.3 0.74 
Fatal cerebral events** 
FS - 1.28 1.42 -4.1 1.5 0.37  - 1.50 1.36 -4.2 1.2 0.28 
LMT-UMS 0.30 1.01 -1.7 2.3 0.77  0.30 0.98 -1.6 2.2 0.76 
LMT-LAA - 0.47 1.47 -3.4 2.4 0.75  - 0.48 1.41 -3.2 2.3 0.74 
ICU stay 
FS - 0.03 0.05 -0.1 0.1 0.56  - 0.03 0.03 -0.09 0.03 0.26 
LMT-UMS - 0.05 0.07 -0.2 0.1 0.29  - 0.05 0.03 -0.11 0.01 0.12 
LMT-LAA 0.04 0.09 -0.1 0.2 0.61  0.05 0.06 -0.1 0.2 0.43 
In-hospital stay 
FS - 0.01 0.02 -0.05 0.03 0.58  - 0.01 0.01 -0.03 0.01 0.35 
LMT-UMS - 0.02 0.01 -0.04 0.01 0.24  - 0.02 0.01 -0.04 0.01 0.07 
LMT-LAA - 0.01 0.02 -0.05 0.03 0.80  - 0.01 0.01 -0.03 0.01 0.56 
30-days death 
FS - 0.41 1.59 -3.5 2.7 0.80  - 0.03 1.53 -3.0 3.0 0.99 
LMT-UMS 0.06 1.31 -2.5 2.6 0.97  0.11 1.27 -2.4 2.6 0.93 
LMT-LAA 1.37 1.49 -1.6 4.3 0.36  1.36 1.43 -1.4 4.2 0.35 
* Severe-acute and severe; ** ischemic and haemorrhagic stroke  
Abbreviations used: FS – full sternotomy; LMT – left anterior mini-thoracotomy; RMT – right anterior mini-thoracotomy; UMS 
– upper mini-sternotomy; LAA – left axillary artery isolation; ICU – intensive care unit 
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Figure legends 
Figure 1 
Evolution of the surgical approach for the HeartWare HVAD implantation. A) Techniques entailing 
outflow graft anastomosis to the ascending aorta: A1 – full sternotomy; A2 – left anterior mini-
thoracotomy and upper mini-sternotomy; A3 – left and right anterior mini-thoracotomy. B) Left 
anterior mini-thoracotomy with outflow graft anastomosis to the left axillary artery. 
 
Figure 2 
Surgical techniques for the outflow graft anastomosis of HeartWare HVAD to the left axillary artery 
(LAA). A) Procedure that applies when the LAA calibre is >8 mm: end-to-end outflow graft 
anastomosis and end-to-side distal LAA connection. B) Procedure used when the LAA calibre is 
<8mm: 8 mm-graft interposition to LAA and end-to-side outflow graft anastomosis.  
 
Figure 3 
Competing risk analysis. 
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